Table 2.
Levels and subclass distribution of anti-ADAMTS13 IgG antibodies in clinical remission following the first acute episode and following a relapse.
| Remission after first episode | Remission after relapse | |
|---|---|---|
| Clinical data | ||
| Number of individuals | 9 | 8 |
| Age (years) | 34 (20–45) | 34 (30–45) |
| Gender (female/male) | 8/1 | 8/0 |
| No of previous episode | 1 | 3 (2–4) |
| Months since first episode | 7 (3–35) | 72 (42–143) |
| Total anti-ADAMTS13 IgG concentration (U/mL) | ||
| IgG | 45.0 (31.5–73.3) | 60.2 (30.6–592.2) |
| Proportion of IgG subclasses (%) | ||
| IgG1 | 23.8 (19.2–41.7) | 25.3 (22.1–31.5) |
| IgG2 | 0.0 (0.0–4.9) | 0.0 (0.0–2.9) |
| IgG3 | 0.0 (0.0–2.0) | 0.0 (0.0–0.6) |
| IgG4 | 71.4 (32.6–80.8) | 73.0 (67.2–76.9) |
| Concentration of IgG subclasses (U/mL) | ||
| IgG1 | 17.6 (6.7–39.4) | 14.0 (8.1–152.0) |
| IgG2 | 0.0 (0.0–3.3) | 0.0 (0.0–18.3) |
| IgG3 | 0.0 (0.0–1.0) | 0.0 (0.0–0.3) |
| IgG4 | 29.6 (10.0–49.85) | 45.7 (24.2–388.5) |
| Dominant subclasses (number of patients) | ||
| IgG1 or IgG3 | 2 (22%) | 0 (0%) |
| IgG4 | 7 (78%) | 8 (100%) |
Results of independent samples are shown; only one (the first) remission sample of each patient was involved in the analysis. Values are expressed as median (IQ range). The subclass with the highest proportion was considered dominant. No statistical analysis was performed because of the low number of samples.